RU2664734C2 - Способ обнаружения внутриклеточных возбудителей инфекции в клетках спермы - Google Patents
Способ обнаружения внутриклеточных возбудителей инфекции в клетках спермы Download PDFInfo
- Publication number
- RU2664734C2 RU2664734C2 RU2014141207A RU2014141207A RU2664734C2 RU 2664734 C2 RU2664734 C2 RU 2664734C2 RU 2014141207 A RU2014141207 A RU 2014141207A RU 2014141207 A RU2014141207 A RU 2014141207A RU 2664734 C2 RU2664734 C2 RU 2664734C2
- Authority
- RU
- Russia
- Prior art keywords
- virus
- sperm
- dna
- cells
- chlamydia
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 82
- 208000015181 infectious disease Diseases 0.000 title claims description 27
- 210000000582 semen Anatomy 0.000 title abstract description 22
- 230000003834 intracellular effect Effects 0.000 title description 17
- 230000002458 infectious effect Effects 0.000 title description 7
- 241000606161 Chlamydia Species 0.000 claims abstract description 33
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 14
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims abstract description 13
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 7
- 241000700584 Simplexvirus Species 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 241000223996 Toxoplasma Species 0.000 claims abstract description 6
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 5
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract description 5
- 241000701027 Human herpesvirus 6 Species 0.000 claims abstract description 5
- 241001263478 Norovirus Species 0.000 claims abstract description 5
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 4
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims abstract description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 4
- 241000125945 Protoparvovirus Species 0.000 claims abstract description 4
- 241000710799 Rubella virus Species 0.000 claims abstract description 4
- 244000052769 pathogen Species 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 22
- 238000000684 flow cytometry Methods 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 108010004729 Phycoerythrin Proteins 0.000 claims description 11
- 238000010166 immunofluorescence Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- JLDSMZIBHYTPPR-UHFFFAOYSA-N Alexa Fluor 405 Chemical compound CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.C12=C3C=4C=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C1=CC=C3C(S(=O)(=O)[O-])=CC=4OCC(=O)N(CC1)CCC1C(=O)ON1C(=O)CCC1=O JLDSMZIBHYTPPR-UHFFFAOYSA-N 0.000 claims description 8
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 claims description 8
- 208000000509 infertility Diseases 0.000 claims description 8
- 230000036512 infertility Effects 0.000 claims description 8
- 231100000535 infertility Toxicity 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- 208000000995 spontaneous abortion Diseases 0.000 claims description 8
- 230000005570 vertical transmission Effects 0.000 claims description 8
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 claims description 6
- 108700012813 7-aminoactinomycin D Proteins 0.000 claims description 6
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 6
- 208000015994 miscarriage Diseases 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 claims description 4
- 239000012117 Alexa Fluor 700 Substances 0.000 claims description 4
- -1 Cascade Yellow Substances 0.000 claims description 4
- 230000007018 DNA scission Effects 0.000 claims description 4
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 4
- PRGGHGIYKMNFCM-UHFFFAOYSA-N acetic acid;3-(aminomethyl)chromen-2-one Chemical compound CC(O)=O.C1=CC=C2OC(=O)C(CN)=CC2=C1 PRGGHGIYKMNFCM-UHFFFAOYSA-N 0.000 claims description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 4
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 230000035935 pregnancy Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims description 3
- AVEQMYZAGPYSNN-UHFFFAOYSA-N 6,8-difluoro-7-hydroxychromen-2-one Chemical class C1=CC(=O)OC2=C(F)C(O)=C(F)C=C21 AVEQMYZAGPYSNN-UHFFFAOYSA-N 0.000 claims description 2
- 208000001951 Fetal Death Diseases 0.000 claims description 2
- 206010055690 Foetal death Diseases 0.000 claims description 2
- 206010021882 Infections and infestations congenital Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 231100000479 fetal death Toxicity 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 210000004995 male reproductive system Anatomy 0.000 claims description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 2
- 108010004469 allophycocyanin Proteins 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 29
- 244000005700 microbiome Species 0.000 abstract description 23
- 241000709687 Coxsackievirus Species 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 79
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 239000000523 sample Substances 0.000 description 16
- 238000011534 incubation Methods 0.000 description 12
- 230000001850 reproductive effect Effects 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 10
- 241000606153 Chlamydia trachomatis Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 206010003883 azoospermia Diseases 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000498849 Chlamydiales Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011246 intracellular protein detection Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 208000008634 oligospermia Diseases 0.000 description 3
- 230000036616 oligospermia Effects 0.000 description 3
- 231100000528 oligospermia Toxicity 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000002312 Teratozoospermia Diseases 0.000 description 2
- 206010058874 Viraemia Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000008722 morphological abnormality Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 231100000527 sperm abnormality Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067162 Asthenospermia Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001517118 Goose parvovirus Species 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000220623 Megaselia rubella Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000035002 Pregnancy of unknown location Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20120100185 | 2012-03-29 | ||
| GR20120100185A GR1008033B (el) | 2012-03-29 | 2012-03-29 | Μεθοδος διερευνησης της παρουσιας ενδοκυτταριων μολυσματικων παραγοντων σε κυτταρα του σπερματος |
| PCT/GR2013/000016 WO2013144662A1 (en) | 2012-03-29 | 2013-03-29 | Method of intracellular infectious agent detection in sperm cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014141207A RU2014141207A (ru) | 2016-05-27 |
| RU2664734C2 true RU2664734C2 (ru) | 2018-08-22 |
Family
ID=48407746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014141207A RU2664734C2 (ru) | 2012-03-29 | 2013-03-29 | Способ обнаружения внутриклеточных возбудителей инфекции в клетках спермы |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150064691A1 (enExample) |
| EP (1) | EP2831588A1 (enExample) |
| JP (1) | JP6301310B2 (enExample) |
| KR (1) | KR20150042146A (enExample) |
| CN (1) | CN104303059B (enExample) |
| AU (3) | AU2013239416A1 (enExample) |
| CA (1) | CA2868707A1 (enExample) |
| CL (1) | CL2014002584A1 (enExample) |
| GR (1) | GR1008033B (enExample) |
| HK (1) | HK1201579A1 (enExample) |
| IL (1) | IL234844A0 (enExample) |
| IN (1) | IN2014DN08201A (enExample) |
| RU (1) | RU2664734C2 (enExample) |
| SG (2) | SG10201704802YA (enExample) |
| WO (1) | WO2013144662A1 (enExample) |
| ZA (1) | ZA201407818B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2738798C1 (ru) * | 2020-08-31 | 2020-12-16 | Василий Васильевич Ашапкин | Способ количественного определения вирусного инфицирования сперматозоидов |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016154286A1 (en) * | 2015-03-23 | 2016-09-29 | Virocyt, Inc. | Evaluating biological material for unassociated virus-size particles of adenovirus or adeno-associated virus viral type |
| CN107121547A (zh) * | 2016-01-21 | 2017-09-01 | 广东和信健康科技有限公司 | 直接免疫荧光检测肠道病毒71型和柯萨奇病毒a16型的试剂盒及其应用 |
| CN111474339A (zh) * | 2020-04-17 | 2020-07-31 | 浙江康佰裕生物科技有限公司 | 一种利用荧光标记痘病毒颗粒的方法及其应用 |
| CN115032391A (zh) * | 2022-06-21 | 2022-09-09 | 成都思瑞多医疗科技有限公司 | 精子唾液酸酶1/3检测试剂盒及其制备方法、检测精子唾液酸酶1/3表达水平的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060520A2 (en) * | 2001-12-24 | 2003-07-24 | Helen Lee | Sample preparation for the detection of infectious agents |
| US20060099661A1 (en) * | 2004-04-16 | 2006-05-11 | Stuart Elizabeth S | Detection and quantification of intracellular pathogens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1027437T3 (da) * | 1997-10-29 | 2008-11-24 | Genentech Inc | Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1 |
| GB0016920D0 (en) * | 2000-07-10 | 2000-08-30 | Univ Cambridge Tech | Decondensation of DNA |
| PT1673105E (pt) * | 2003-07-25 | 2007-06-20 | Serono Lab | ''utilizaçao da hormona estimulante do folículo para a redução de aberrações cromossómicas em espermatozóides em indivíduos do sexo masculino'' |
-
2012
- 2012-03-29 GR GR20120100185A patent/GR1008033B/el active IP Right Grant
-
2013
- 2013-03-29 AU AU2013239416A patent/AU2013239416A1/en not_active Abandoned
- 2013-03-29 CN CN201380023706.3A patent/CN104303059B/zh not_active Expired - Fee Related
- 2013-03-29 CA CA2868707A patent/CA2868707A1/en not_active Abandoned
- 2013-03-29 SG SG10201704802YA patent/SG10201704802YA/en unknown
- 2013-03-29 EP EP13721796.4A patent/EP2831588A1/en not_active Withdrawn
- 2013-03-29 RU RU2014141207A patent/RU2664734C2/ru not_active IP Right Cessation
- 2013-03-29 WO PCT/GR2013/000016 patent/WO2013144662A1/en not_active Ceased
- 2013-03-29 US US14/387,794 patent/US20150064691A1/en not_active Abandoned
- 2013-03-29 IN IN8201DEN2014 patent/IN2014DN08201A/en unknown
- 2013-03-29 JP JP2015502463A patent/JP6301310B2/ja not_active Expired - Fee Related
- 2013-03-29 KR KR20147029210A patent/KR20150042146A/ko not_active Ceased
- 2013-03-29 SG SG11201406096QA patent/SG11201406096QA/en unknown
- 2013-03-29 HK HK15101974.1A patent/HK1201579A1/xx unknown
-
2014
- 2014-09-26 CL CL2014002584A patent/CL2014002584A1/es unknown
- 2014-09-28 IL IL234844A patent/IL234844A0/en unknown
- 2014-10-27 ZA ZA2014/07818A patent/ZA201407818B/en unknown
-
2018
- 2018-12-06 AU AU2018274968A patent/AU2018274968A1/en not_active Abandoned
- 2018-12-07 AU AU2018275005A patent/AU2018275005A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060520A2 (en) * | 2001-12-24 | 2003-07-24 | Helen Lee | Sample preparation for the detection of infectious agents |
| US20060099661A1 (en) * | 2004-04-16 | 2006-05-11 | Stuart Elizabeth S | Detection and quantification of intracellular pathogens |
Non-Patent Citations (1)
| Title |
|---|
| Уреаплазма (Уреаплазмоз). Информация с сайта "ИМЕДИС +", г.Екатеринбург; 2010. стр.1-2 [Найдено 06.04.2017] [он-лайн], Найдено из Интернет: URL: http://imedis-plus.ru/content/%D1%83%D1%80%D0%B5%D0%B0%D0%BF%D0%BB%D0%B0%D0%B7%D0%BC%D0%B0-%D1%83%D1%80%D0%B5%D0%B0%D0%BF%D0%BB%D0%B0%D0%B7%D0%BC%D0%BE%D0%B7. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2738798C1 (ru) * | 2020-08-31 | 2020-12-16 | Василий Васильевич Ашапкин | Способ количественного определения вирусного инфицирования сперматозоидов |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2868707A1 (en) | 2013-10-03 |
| KR20150042146A (ko) | 2015-04-20 |
| CN104303059B (zh) | 2016-08-17 |
| HK1201579A1 (en) | 2015-09-04 |
| AU2018275005A1 (en) | 2019-01-03 |
| RU2014141207A (ru) | 2016-05-27 |
| GR20120100185A (el) | 2013-10-15 |
| SG10201704802YA (en) | 2017-07-28 |
| CL2014002584A1 (es) | 2015-06-19 |
| ZA201407818B (en) | 2016-05-25 |
| US20150064691A1 (en) | 2015-03-05 |
| IL234844A0 (en) | 2014-12-31 |
| WO2013144662A1 (en) | 2013-10-03 |
| IN2014DN08201A (enExample) | 2015-05-01 |
| JP6301310B2 (ja) | 2018-03-28 |
| SG11201406096QA (en) | 2014-10-30 |
| AU2013239416A1 (en) | 2014-10-16 |
| CN104303059A (zh) | 2015-01-21 |
| EP2831588A1 (en) | 2015-02-04 |
| JP2015513103A (ja) | 2015-04-30 |
| GR1008033B (el) | 2013-11-18 |
| AU2018274968A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ribeiro et al. | Inter‐and intra‐laboratory standardization of TUNEL assay for assessment of sperm DNA fragmentation | |
| Zhang et al. | Early apoptotic changes in human spermatozoa and their relationships with conventional semen parameters and sperm DNA fragmentation | |
| AU2018274968A1 (en) | Method of intracellular infectious agent detection in sperm cells | |
| Barbăroșie et al. | Diagnostic value of advanced semen analysis in evaluation of male infertility | |
| Stamm | Diagnosis of Chlamydia trachomatis genitourinary infections | |
| Sigman et al. | Semen analysis and sperm function assays: what do they mean? | |
| Ajina et al. | Assessment of human sperm DNA integrity using two cytochemical tests: Acridine orange test and toluidine blue assay | |
| Varum et al. | Characterization of human sperm populations using conventional parameters, surface ubiquitination, and apoptotic markers | |
| JP2019090814A (ja) | サンプル分析のための方法、機器、及びシステム | |
| Reyes-Méndez et al. | Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV antigen test | |
| Kijlstra | The value of laboratory testing in uveitis | |
| RU2362167C1 (ru) | Способ диагностики мужского бесплодия | |
| Kimura et al. | Is it possible to detect the presence of adenovirus in conjunctiva before the onset of conjunctivitis? | |
| Eley | How to detect Chlamydia trachomatis in males? | |
| Yousuf et al. | A review on the diagnosis of feline infectious peritonitis | |
| Umapathy et al. | Sperm characteristics and accessory sex gland functions in HIV-infected men | |
| Sweet et al. | RNA in-situ hybridization for pathology-based diagnosis of feline infectious peritonitis (FIP): current diagnostics for FIP and comparison to the current gold standard | |
| JP2007532913A (ja) | 細胞内病原体の検出法および定量化法 | |
| Hodjat et al. | Increased sperm ubiquitination correlates with abnormal chromatin integrity | |
| Gerber et al. | Prenatal diagnosis of congenital cytomegalovirus infection by detection of immunoglobulin M antibodies to the 70-kd heat shock protein in fetal serum | |
| Sharma et al. | TUNEL assay by benchtop flow cytometer in clinical laboratories | |
| Porge et al. | THE EFFECT OF HUMAN PAPILLOMA VIRUS ON SPERMATOGENESIS | |
| Martins et al. | Assessment of Sperm Chromatin Damage by TUNEL Method Using Benchtop Flow Cytometer | |
| Reyad | Conventional and recent approaches for diagnosis of malaria | |
| CN115290536A (zh) | 一种改良的微量淋巴毒交叉配型检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200330 |